SCHEMBL3014464

SCHEMBL3014464

Cc1ccc(-c2csc(N3CCN(S(=O)(=O)c4c(F)cccc4F)CC3)n2)cc1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.62
L3MBTL1 Q9Y468 3/20 0.62
ALDH1A1 P00352 2/20 0.62
MAPK1 P28482 3/20 0.60
LMNA P02545 3/20 0.59
MEN1 O00255 3/20 0.59
KMT2A Q03164 3/20 0.59
MAPT P10636 3/20 0.59
USP2 O75604 1/20 0.53
RECQL P46063 1/20 0.53
HSD17B10 Q99714 1/20 0.53
AR P10275 4/20 0.52
PKM P14618 3/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
PKLR P30613 2/20 0.50
HTT P42858 1/20 0.47
THRB P10828 2/20 0.47
POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3014017 0.90 SMN1; SMN2 (0.55) SMN1; SMN2L3MBTL1ALDH1A1MAPK1LMNA
SCHEMBL3005812 0.90 LMNA (0.67) SMN1; SMN2L3MBTL1ALDH1A1MAPK1LMNA
SCHEMBL3023519 0.89 MAPT (0.59) SMN1; SMN2L3MBTL1ALDH1A1MAPK1LMNA
SCHEMBL3013174 0.89 SMN1; SMN2 (0.62) SMN1; SMN2L3MBTL1ALDH1A1MAPK1LMNA
SCHEMBL3007433 0.89 SMN1; SMN2 (0.65) SMN1; SMN2L3MBTL1ALDH1A1MAPK1LMNA
SCHEMBL3003137 0.89 ALDH1A1 (0.56) SMN1; SMN2L3MBTL1ALDH1A1MAPK1LMNA
SCHEMBL3008789 0.89 MAPT (0.63) SMN1; SMN2L3MBTL1ALDH1A1MAPK1LMNA
SCHEMBL3000559 0.89 LMNA (0.59) SMN1; SMN2L3MBTL1ALDH1A1MAPK1LMNA
SCHEMBL3012611 0.87 ALDH1A1 (0.59) SMN1; SMN2L3MBTL1ALDH1A1MAPK1LMNA
SCHEMBL3011269 0.87 LMNA (0.57) SMN1; SMN2L3MBTL1ALDH1A1MAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885L3MBTL1 1847/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.